On April 17, 2025, major shareholder Orbimed Advisors Llc sold 77,090 shares of Passage Bio stock. The shares were sold at an average price of $0.33 per share, totaling $25,439.70.
Following the completion of this sale, Orbimed Advisors Llc now owns 6,885,572 shares in Passage Bio. This transaction represents a 1.11% decrease in their position.
The sale was disclosed in a legal filing with the SEC. This adjustment by a significant institutional investor is a notable event for the company's shareholder base.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.